Chuangsheng Group - B: Exploration of strategic cooperation agreements with Huajian Medical Holdings Limited and its two subsidiaries to explore the potential financing of real-world asset tokenization for the development of innovative cancer therapies.

Chuangsheng Group - Announcement B, on September 21, 2025, the company signed a non-legally binding strategic cooperation agreement with its wholly-owned subsidiary Transcenta Oncology Inc., Huajian Medical Holdings Limited, and its two subsidiaries. According to the agreement, the parties will explore the potential issuance of tokens for real-world assets through the Ethereum blockchain to fund the pre-clinical and clinical development work of one or more selected projects of six potential "first-in-class" and/or "best-in-class" cancer innovative therapies. If the token issuance is successful, the proceeds from future financing will be used to accelerate the clinical and pre-clinical development of multiple innovative cancer antibody projects.